Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System

NACompletedINTERVENTIONAL
Enrollment

477

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

January 10, 2024

Study Completion Date

January 10, 2024

Conditions
Atrial Fibrillation
Interventions
DEVICE

Mapping and Ablation

Minimally invasive catheter mapping and ablation procedure

Trial Locations (23)

10029

Icahn School of Medicine at Mount Sinai, New York

10075

Northwell Health, New York

11219

Maimonides Medical Center, Brooklyn

17043

University of Pittsburgh Medical Center Pinnacle Health, Wormleysburg

18901

Doylestown Hospital, Doylestown

20010

MedStar Washington Hospital Center, Washington D.C.

23507

Sentara Norfolk General Hospital, Norfolk

32803

AdventHealth Orlando, Orlando

34102

Naples Heart Institute, Naples

35243

Arrhythmia Institute at Grandview, Birmingham

37232

Vanderbilt Medical Center, Nashville

43210

The Ohio State University Wexner Medical Center, Columbus

43214

The OhioHealth Research Institute, Columbus

44195

Cleveland Clinic Foundation, Cleveland

72401

Arrhythmia Research Group, Jonesboro

78705

Texas Cardiac Arrhythmia Research Foundation, Austin

85006

Banner University Medical Center Phoenix, Phoenix

90404

Pacific Heart Institute, Santa Monica

6093000

Shamir Medical Center, Zrifin

02114

Massachusetts General Hospital, Boston

370 01

Nemocnice Ceske Budejovice, České Budějovice

140 21

Institut Klinicke a Experimentani Mediciny, Prague

150 30

Nemocnice Na Homolce, Prague

All Listed Sponsors
lead

Medtronic Cardiac Ablation Solutions

INDUSTRY

NCT05120193 - Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System | Biotech Hunter | Biotech Hunter